Literature DB >> 16032412

Chronic treatment with duloxetine is necessary for an anxiolytic-like response in the mouse zero maze: the role of the serotonin transporter.

K B Troelsen1, E Ø Nielsen, N R Mirza.   

Abstract

RATIONALE: Monoamine transporter inhibitor antidepressants have anxiolytic efficacy in man. However, preclinical data poorly reflect this, either because (1) few studies assess chronic antidepressant treatment in animal models, (2) antidepressants are anxiogenic after acute treatment; and (3) animal models of anxiety are insensitive to antidepressants.
OBJECTIVE: We address issues (1) and (2) and ascertain potential mechanisms mediating anxiolytic effects demonstrated.
METHODS: The effect of acute treatment with seven antidepressants covering the classes selective serotonin reuptake inhibitors, serotonin-noradrenaline reuptake inhibitors, noradrenaline reuptake inhibitors and tricyclic antidepressants were compared with the benzodiazepine, chlordiazepoxide, on the mouse zero maze, an unconditioned model of anxiety. Furthermore, citalopram, duloxetine, reboxetine and amitriptyline were assessed after chronic administration (10 mg/kg p.o., 21 days, twice daily) in this model. In mice treated chronically, (a) the hypothermic response to serotonin (5-HT)1A and 5-HT1B receptor ligands, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OHDPAT) and m-chlorophenyl piperazine (mCPP), respectively, was assessed and (b) serotonin transporter (SERT) and noradrenaline transporter (NET) densities in the cortex and hippocampus, respectively, were determined.
RESULTS: None of the antidepressants were anxiolytic after acute treatment, although reboxetine, duloxetine and amitriptyline were anxiogenic. Only chronic treatment with duloxetine induced an anxiolytic effect, which was dissociable from nonspecific motor effects. Duloxetine reduced SERT density in the cortex by approximately 75% compared to control, with no effect on NET density in the hippocampus. Citalopram and amitriptyline significantly reduced SERT density by approximately 20%, whereas reboxetine selectively reduced NET density. All drugs reduced the hypothermic response to 8-OHDPAT and mCPP.
CONCLUSION: Duloxetine was anxiolytic after chronic but not acute treatment, reflecting clinical experience with antidepressants in general. Duloxetine's anxiolytic-like profile may be ascribed to the considerable reduction in the density of the SERT in the cortex.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16032412     DOI: 10.1007/s00213-005-0032-5

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  51 in total

Review 1.  Autoregulation of serotonin neurons: role in antidepressant drug action.

Authors:  G Piñeyro; P Blier
Journal:  Pharmacol Rev       Date:  1999-09       Impact factor: 25.468

Review 2.  Animal models of depression: an overview.

Authors:  P Willner
Journal:  Pharmacol Ther       Date:  1990       Impact factor: 12.310

Review 3.  Basic psychopharmacology of antidepressants, part 1: Antidepressants have seven distinct mechanisms of action.

Authors:  S M Stahl
Journal:  J Clin Psychiatry       Date:  1998       Impact factor: 4.384

Review 4.  Potential use of drugs modulating 5HT activity in the treatment of anxiety.

Authors:  C R Gardner
Journal:  Gen Pharmacol       Date:  1988

Review 5.  Role of the serotonergic system in the forced swimming test.

Authors:  F Borsini
Journal:  Neurosci Biobehav Rev       Date:  1995       Impact factor: 8.989

6.  Paroxetine binding to the rat norepinephrine transporter in vivo.

Authors:  M J Owens; D L Knight; C B Nemeroff
Journal:  Biol Psychiatry       Date:  2000-05-01       Impact factor: 13.382

7.  Association of the serotonin transporter promoter regulatory region polymorphism and obsessive-compulsive disorder.

Authors:  D Bengel; B D Greenberg; G Corá-Locatelli; M Altemus; A Heils; Q Li; D L Murphy
Journal:  Mol Psychiatry       Date:  1999-09       Impact factor: 15.992

8.  Behavioral pharmacology of AR-A000002, a novel, selective 5-hydroxytryptamine(1B) antagonist.

Authors:  T J Hudzik; M Yanek; T Porrey; J Evenden; C Paronis; M Mastrangelo; C Ryan; S Ross; C Stenfors
Journal:  J Pharmacol Exp Ther       Date:  2003-03       Impact factor: 4.030

9.  Serotonin receptor 1A knockout: an animal model of anxiety-related disorder.

Authors:  S Ramboz; R Oosting; D A Amara; H F Kung; P Blier; M Mendelsohn; J J Mann; D Brunner; R Hen
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

10.  LY248686, a new inhibitor of serotonin and norepinephrine uptake.

Authors:  D T Wong; F P Bymaster; D A Mayle; L R Reid; J H Krushinski; D W Robertson
Journal:  Neuropsychopharmacology       Date:  1993-01       Impact factor: 7.853

View more
  10 in total

Review 1.  5-HT(1A) receptor function in major depressive disorder.

Authors:  Jonathan Savitz; Irwin Lucki; Wayne C Drevets
Journal:  Prog Neurobiol       Date:  2009-02-07       Impact factor: 11.685

2.  Differential effects of acute and repeated citalopram in mouse models of anxiety and depression.

Authors:  Cedric Mombereau; Tamar L Gur; Jennifer Onksen; Julie A Blendy
Journal:  Int J Neuropsychopharmacol       Date:  2009-12-14       Impact factor: 5.176

3.  The role of duloxetine in the treatment of anxiety disorders.

Authors:  Domenico De Berardis; Nicola Serroni; Alessandro Carano; Marco Scali; Alessandro Valchera; Daniela Campanella; Alessandro D'Albenzio; Berardo Di Giuseppe; Francesco Saverio Moschetta; Rosa Maria Salerno; Filippo Maria Ferro
Journal:  Neuropsychiatr Dis Treat       Date:  2008-10       Impact factor: 2.570

4.  Chronic oral nicotine increases brain [3H]epibatidine binding and responsiveness to antidepressant drugs, but not nicotine, in the mouse forced swim test.

Authors:  Jesper T Andreasen; Elsebet O Nielsen; John P Redrobe
Journal:  Psychopharmacology (Berl)       Date:  2009-05-12       Impact factor: 4.530

5.  Insensitivity of NMRI mice to selective serotonin reuptake inhibitors in the tail suspension test can be reversed by co-treatment with 5-hydroxytryptophan.

Authors:  Jacob P R Jacobsen; Elsebet Ø Nielsen; Rene Hummel; John Paul Redrobe; Naheed Mirza; Pia Weikop
Journal:  Psychopharmacology (Berl)       Date:  2008-05-22       Impact factor: 4.530

6.  In vivo effect of antidepressants on [3H]paroxetine binding to serotonin transporters in rat brain.

Authors:  Subhash M Nadgir; Manish Malviya
Journal:  Neurochem Res       Date:  2008-04-25       Impact factor: 3.996

7.  Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians.

Authors:  Hannu Koponen; Christer Allgulander; Janelle Erickson; Eduardo Dunayevich; Yili Pritchett; Michael J Detke; Susan G Ball; James M Russell
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

8.  Effect of a combination of duloxetine with hydroxyzine on experimental models of anxiety in mice.

Authors:  Sonam Patel; Pravin Popatrao Kale; Veeranjaneyulu Addepalli; Amrita Sarkar; Jay Savai
Journal:  Indian J Pharmacol       Date:  2015 Mar-Apr       Impact factor: 1.200

9.  Duloxetine in the treatment of generalized anxiety disorder.

Authors:  Trevor R Norman; James S Olver
Journal:  Neuropsychiatr Dis Treat       Date:  2008-12       Impact factor: 2.570

10.  Differential BDNF responses of triple versus dual reuptake inhibition in neuronal and astrocytoma cells as well as in rat hippocampus and prefrontal cortex.

Authors:  Jos Prickaerts; Jochen De Vry; Janneke Boere; Gunter Kenis; Maria S Quinton; Sharon Engel; Larry Melnick; Rudy Schreiber
Journal:  J Mol Neurosci       Date:  2012-05-13       Impact factor: 3.444

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.